Is the Nanosonics share price a buy?

The Nanosonics Ltd. (ASX: NAN) share price still sits well below the 52-week high of $3.86 despite continuing to rally with global markets since the pre-Christmas plunge.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Nanosonics Ltd. (ASX: NAN) share price is currently trading at $3.50, down 0.14% for the session, and still well below its 52-week high of $3.86 despite continuing to rally with global markets since the pre-Christmas plunge.

Nanosonics is an ASX200 listed healthcare company that specialises in the development and commercialisation of infection control solutions.  It has a global footprint and is approved for sale across most major markets.

Its global installed base of Trophon devices grew to 17.7k in FY2018 with continued growth expected in FY2019.  The total opportunity for installed bases is currently estimated to be 120k, meaning only 15% of the total market has been penetrated.

Along with the growth in installed bases, Nanosonics is also beginning to benefit from a second revenue stream as customers begin to replace Trophon units that are more than 5 years old.  This additional area of work is set to grow substantially over the next three financial years, as a large proportion of customers currently have devices that are three to five years old.

Looking further ahead, continued changes in guidelines regarding disinfection control of semi-critical probes will provide positive tailwinds to sales growth.  The re-negotiation of a major agreement with General Electric Company (NYSE: GE) at the start of FY2020 is also set to result in a material increase in margins.

Whilst there is a clear growth runway for Nanosonics' Trophon devices, some financial measures were softer than anticipated in the FY2018 results.  Sales Revenue was $7M lower than FY17, with Distributors running down inventories due to the pending launch of the Trophon2 device.  Operating expenses were also up in FY2018, largely due to increasing the number of employees to support product expansion. Despite the softer results, the cash position is very healthy at ~$69M and will support further expansion.

Nanosonics is due to report its first-half FY19 earnings on February 25.

So, is the Nanosonics share price a buy?

With earnings per share expected to grow three-fold by 2020, Nanosonics could represent a fantastic buy and hold option for your portfolio.  It has a product that is difficult to replicate and is supported by regulation along with sticky earnings, where a customer is unlikely to quickly change provider once using the Trophon device.  This could lead to the ability to increase margins via price once the company is happy with their market share position.

Looking at its ratios, Nanosonics is currently trading at an astronomical P/E of 183, almost ten times the sector average so its valuation currently looks stretched.  I think it's worthwhile to wait for a pullback and will just keep it in the watchlist for now.

Other ASX healthcare growth shares that may be worth looking into which could be more reasonably valued are ResMed Inc (ASX: RMD) and Pro Medicus Limited (ASX: PME).

Motley Fool contributor Michael Guinery owns shares in Nanosonics Limited, Pro Medicus Ltd and Resmed Inc. The Motley Fool Australia's parent company Motley Fool Holdings Inc. recommends Pro Medicus Ltd. The Motley Fool Australia owns shares of and has recommended Nanosonics Limited and Pro Medicus Ltd. The Motley Fool Australia has recommended ResMed Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

A man looking at his laptop and thinking.
Share Gainers

Here are the top 10 ASX 200 shares today

Investors finished the trading week on a sour note today.

Read more »

Happy teen friends jumping in front of a wall.
Share Gainers

4 ASX 200 stocks smashing the benchmark this week

Investors are sending these four ASX 200 stocks soaring this week. But why?

Read more »

A happy young couple lie on a wooden deck using a skateboard for a pillow.
Broker Notes

Bell Potter says this growing ASX 200 stock can rise over 40%

Big returns could be on the cards for buyers of this stock.

Read more »

Broker written in white with a man drawing a yellow underline.
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »

A couple makes silly chip moustache faces and take a selfie on their phone.
Share Market News

Which delivered superior returns in FY25: CSL, A2 Milk, or Telstra shares?

We review the share price growth and dividend income delivered to investors in FY25.

Read more »

Woman with an amazed expression has her hands and arms out with a laptop in front of her.
Share Gainers

Why IGO, Johns Lyng, Lynas, and Web Travel shares are pushing higher today

These shares are ending the week on a high. But why?

Read more »

Person with thumbs down and a red sad face poster covering the face.
Share Fallers

Why Imricor, Ora Banda, Ventia, and Vulcan shares are dropping today

These shares are ending the week in the red. But why?

Read more »

Man with rocket wings which have flames coming out of them.
Resources Shares

Up 23% today, why Macquarie forecasts this ASX 200 mining stock could rocket another 33%

Macquarie forecasts more outsized gains to come for this surging ASX 200 mining stock.

Read more »